| Phosphorothioate (PS) |
Backbone |
Nuclease resistance, improved stability, enhanced protein binding |
Standard ASO designs across mechanisms |
Industry-standard backbone |
| 2′-O-Methyl (2′-OMe) |
Sugar |
Improves stability, binding affinity, and nuclease resistance |
Steric-blocking ASO, splice-switching ASO, antimiR |
Common non-cleaving chemistry |
| 2′-MOE |
Sugar |
High affinity, good nuclease resistance, broad therapeutic use |
Gapmer wings, steric-blocking ASO, miRNA inhibition |
Balanced potency and safety profile |
| 2′-Fluoro (2′-F) |
Sugar |
Increased duplex stability and nuclease resistance |
Hybrid ASO designs and RNA-targeting applications |
Useful in mixed-modification designs |
| LNA / BNA |
Bridged sugar |
Very high affinity, improved specificity, shorter designs |
All ASO types, high-potency targeting |
Strong binding; placement matters |
| cEt (Constrained Ethyl) |
Sugar analog |
LNA-like affinity, improved manufacturability, strong potency |
Advanced gapmer and therapeutic-style ASO designs |
Next-generation LNA alternative |
| PNA |
Backbone analog |
Neutral backbone, extremely high affinity, resistant to enzymes |
Steric-blocking, diagnostics, research |
Does not activate RNase H |
| PMO / Morpholino |
Backbone analog |
Neutral backbone, high stability, no RNase H activation |
Steric-blocking and splice-switching |
Gold standard for splice modulation |
| TMO / Tricyclo-DNA |
Constrained analog |
Enhanced affinity, structural rigidity, improved specificity |
Steric-blocking and specialized RNA targets |
Advanced analog platform |
| Stereopure PS ASO |
Backbone optimization |
Defined chirality, improved potency, reduced off-target effects |
High-potency therapeutic development |
Next-generation backbone control |
| GalNAc Conjugate |
Conjugate |
Liver-targeting delivery, enhanced uptake, lower dose potential |
Liver disease and metabolic targets |
Clinically validated delivery strategy |
| Peptide Conjugate |
Conjugate |
Improved cell penetration, tissue targeting, versatile delivery |
Extrahepatic delivery, oncology, CNS research |
Flexible targeting option |
| Cholesterol / Lipid Conjugate |
Conjugate |
Enhanced membrane uptake, improved PK profile, tissue distribution |
Systemic delivery and preclinical studies |
Can improve potency and exposure |